Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

456P - Tumor response to irinotecan is associated with IL-10 expression level in metastatic colorectal cancer - Results from mCRC biomarker study

Date

17 Sep 2020

Session

E-Poster Display

Topics

Tumour Site

Colon and Rectal Cancer

Presenters

Jinjia Chang

Citation

Annals of Oncology (2020) 31 (suppl_4): S409-S461. 10.1016/annonc/annonc270

Authors

J. Chang1, W. Zhang2, W. Li2

Author affiliations

  • 1 Department Of Medical Oncology, Fudan University Shanghai Cancer Center, 200032 - Shanghai/CN
  • 2 Department Of Medical Oncology, Fudan University Shanghai Cancer Center, 200032 - Shanghai/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 456P

Background

Metastatic colorectal cancer (mCRC) is a major cause of death of malignant tumor and the valuable prognostic biomarker for chemotherapy is crucial in decreasing mortality. IL-10 has been reported decreased after surgery and increased when tumor recurred in operable CRC. However, the prognostic impact of IL-10 in mCRC is still unclear. In this study, we aimed to clarify the prognostic role of IL-10 in mCRC undergoing standard first-line chemotherapy.

Methods

The retrospective study recruited 264 mCRC patients between January 2012 to December 2016 (NCT03532711). All the enrolled patients received oxaliplatin-containing or irinotecan-containing regimen. The expression level of IL-10 in 232 patients’ serum and 68 patients’ tumor tissue was examined. The relationships between IL-10 and clinicopathological characteristics were analyzed. Kaplan- Meier method and Cox regression were used to evaluate the prognostic impact of IL-10.

Results

The median concentration of IL-10 was 7.60 pg/mL before treatment and 11.08 pg/mL after treatment, which suggested that IL-10 level was significantly increased by treatment with chemotherapeutic regimen (p = 0.000). By utilizing univariate and multivariate Cox proportional hazard analyses, we found that low IL-10 level in serum was significantly associated with better overall survival (OS) of mCRC patients treated with irinotecan-containing regimen, with optimal cutoff values of 5.525pg/mL, respectively (p =0.002). In addition, low IL-10 expression level in tumor tissue was significantly associated with better OS for irinotecan-containing regimen (p = 0.023).

Conclusions

Our study demonstrated that IL-10 could act as a prognostic biomarker for mCRC patients undergoing irinotecan-containing chemotherapy.

Clinical trial identification

NCT03532711 (retrospectively registered: May 20th, 2018).

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.